Anti-dumping duty may be imposed on ofloxacin imports from China

19 Aug 2022 , 04:46 PM

To protect domestic players from low-cost imports from the neighboring country, the trade ministry has recommended imposing anti-dumping duties on Chinese ofloxacin, a medication used to treat certain illnesses, for five years.

After determining through its investigation that the product had been exported to India at dumping prices, which had an effect on the domestic industry, the Directorate General of Trade Remedies (DGTR) has proposed the tariff on imports of "ofloxacin" and its intermediates from China.

According to a notification from the directorate, "The authority finds it necessary and proposes the implementation of the anti-dumping duty for a period of 5 years." Bronchitis, pneumonia, infections of the skin, bladder, urinary system, and prostate are just a few of the illnesses that are treated with ofloxacin.

Following a complaint from Aarti Drugs Ltd on the dumping and beginning of the investigation, DGTR carried out the investigation. The ministry is managed by the directorate. The recommended duty is in the range of US $0.53 to the US $7.03 per kilogram. The decision to enforce these obligations rests with the finance ministry.

The World Trade Organization (WTO) regime permits the implementation of anti-dumping duties. The responsibility is to ensure honest business practices and level the playing field between domestic manufacturers and exporters and those from other countries.

Additionally, the department of revenue reported that, contrary to the DGTR's recommendation, the government has chosen not to prolong anti-dumping duties on "textured tempered coated and un-coated glass" from China. To protect domestic players from low-cost imports, the directorate had recommended in May that anti-dumping duties on Chinese solar glass be maintained for another two years.